For the Inventor, By the Inventor

Enter assignee name

Menlo Park, CA, United States of America

Corcept Therapeutics Incorporated

USPTO Granted Patents = 130

CIPO Patents = 11

EPO Patents = 28

Trademarks = 9

Forward Citations = 1,128

Loading Chart...

Loading Chart...

85 inventors (with patents filed for the assignee):

Hazel Joan Hunt (54 out of 56 patents)

Joseph K Belanoff (35 out of 38 patents)

Andreas G Moraitis (31 out of 32 patents)

4. Nicholas Charles Ray (16 out of 38 patents)

5. Iain Walters (15 out of 27 patents)

6. Robin D Clark (12 out of 74 patents)

7. Tony Johnson (10 out of 13 patents)

8. Thaddeus S Block (8 out of 8 patents)

9. Benoit Gourdet (6 out of 8 patents)

10. Karen Williams (6 out of 16 patents)

11. Coleman Gross (5 out of 5 patents)

12. Lorna Duffy (5 out of 10 patents)

13. Jeffrey Mark Dener (5 out of 5 patents)

14. Stacie Shepherd (4 out of 4 patents)

15. Joseph Custodio (4 out of 4 patents)

Core Competencies:

Glucocorticoid Receptor Modulators

Selective Glucocorticoid Receptor Antagonists

Dazucorilant

Heteroaryl-Ketone Fused Azadecalin

Pyrimidine Cyclohexyl Compounds

Neuroepithelial Tumors

Cushing's Syndrome

Pancreatic Cancer

Cervical Cancer

Somatostatin-Receptor Positive Tumors

Fatty Liver Disease

Checkpoint Inhibitors

130 patents: Sort by Forward Citations

1. 12440487 - Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist (2025-10-14),

2. 12433882 - Treatments for amyotrophic lateral sclerosis using dazucorilant (2025-10-07),

3. 12370188 - Formulations of dazucorilant, a glucocorticoid receptor modulator (2025-07-29),

4. 12370175 - Glucocorticoid receptor modulators to treat pancreatic cancer (2025-07-29),

5. 12336985 - Methods for shrinking pituitary tumors (2025-06-24),

6. 12290551 - Methods for imaging and treatment of somatostatin-receptor positive tumors (2025-05-06),

7. 12285425 - Glucocorticoid receptor modulators to treat cervical cancer (2025-04-29),

8. 12263169 - Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators (2025-04-01),

9. 12226417 - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists (2025-02-18),

10. 12226412 - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2025-02-18),

11. 12180186 - Quaternary indazole glucocorticoid receptor antagonists (2024-12-31),

12. 12171760 - Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors (2024-12-24),

13. 12152028 - Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2024-11-26),

14. 12144812 - Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators (2024-11-19),

15. 12139486 - Octahydro fused azadecalin glucocorticoid receptor modulators (2024-11-12),

Corcept Therapeutics Incorporated is a pharmaceutical company that focuses on developing drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. Their research and development efforts primarily revolve around discovering and commercializing selective cortisol modulators, which are small molecule drugs that selectively block the effects of cortisol. With a mission to improve the lives of patients, Corcept Therapeutics is committed to advancing innovative therapies and improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

130 Patents

#11 in Menlo Park, CA

#660 in California

#2,855 in US

#5,994 in the World

Menlo Park, CA, United States of America

Corcept Therapeutics Incorporated

Forward Citations = 1,128

85 inventors:

Hazel Joan Hunt (54 out of 56 patents)

Joseph K Belanoff (35 out of 38 patents)

Andreas G Moraitis (31 out of 32 patents)

4. Nicholas Charles Ray (16 out of 38 patents)

5. Iain Walters (15 out of 27 patents)

Please report any incorrect information to support@idiyas.com

Loading…